Acute Decompensated Heart Failure

Acute Decompensated Heart Failure (ADHF)

What is ADHF?

Acute Decompensated Heart Failure (ADHF) is the rapid onset or worsening of signs and symptoms of heart failure requiring urgent therapy and often hospitalization.

It may occur as:

De novo HF (newly diagnosed)
Acute decompensation of chronic HF
Progression to cardiogenic shock

Major guidelines:

American Heart Association (AHA)
European Society of Cardiology (ESC)

Table of Contents

Pathophysiology of ADHF

Elevated LV filling pressure → Pulmonary congestion
Reduced cardiac output → Hypoperfusion
Neurohormonal activation
Renal congestion → Cardiorenal syndrome

In most cases, hospitalization in heart failure is driven by volume overload with pulmonary and/or venous congestion, reflected by elevated right- and left-sided filling pressures.

Sympathetic activation reduces venous capacitance, shifting blood from reservoirs (like the splanchnic circulation) to the heart, thereby increasing filling pressures without increasing total body volume.

Although weight gain is a simple marker of worsening heart failure, it is not a sensitive indicator in all patients.

Hemodynamic Profiles

Profile	Congestion	Perfusion	Clinical Type
Warm & Wet	Yes	Adequate	Most common(80%)
Cold & Wet	Yes	Poor	High mortality
Cold & Dry	No	Poor	Hypovolemic / overdiuresed
Warm & Dry	No	Adequate	Compensated

Precipitating Factors

Remember: “CHAMP”

C – Acute Coronary Syndrome
H – Hypertensive crisis
A – Arrhythmia (AF common)
M – Mechanical cause (MR, VSD),Myocarditis
P – Pulmonary embolism,Peripartum cardiomyopathy

Others:

Acute volume overload(diuretic nonadherence )
Acute hypovolemia(over-diuresis)
Bradyarrhythmia
Tachyarrhythmia
Prosthetic valve dysfunction (e.g., thrombosis)
Infection
Anemia
Thyroid disorders
Non-compliance
Renal failure
NSAIDs

SCAI SHOCK CLASSIFICATION

The Society for Cardiovascular Angiography & Interventions (SCAI) Shock Classification

Stage	Clinical / Hemodynamic Features	Typical Findings
🟢 A At Risk	No shock; patient has condition that may progress to shock	ACS, acute/decompensated HF, myocarditis, arrhythmia, structural heart disease
🟡 B Beginning Shock	Relative hypotension or tachycardia without hypoperfusion	SBP usually <90 mmHg or MAP <60–65; HR ≥100; may have elevated filling pressures
🟠 C Classic Shock	Hypoperfusion requiring intervention(Established cardiogenic shock)	Hypotension, cool extremities, altered mentation, oliguria, elevated lactate; usually requires vasopressor/inotrope
🔴 D Deteriorating Shock	Shock not responding adequately to initial therapy	Persistent hypotension/hypoperfusion despite initial pharmacologic or mechanical support; worsening lactate, renal function, etc.
⚫ E Extremis	Refractory shock with impending or actual circulatory collapse	Severe hypotension, profound hypoperfusion, severe acidosis/lactate elevation, altered consciousness; multiple vasopressors/MCS; cardiac arrest may occur

Symptoms in ADHF

Symptom	Mechanism
Dyspnea on exertion(most common symptom of hypervolemic ADHF,	↑ LV filling pressure → pulmonary venous congestion → ↓ lung compliance
Orthopnea	Supine position ↑ venous return → ↑ pulmonary capillary pressure
Paroxysmal nocturnal dyspnea (PND)	Nocturnal fluid redistribution + reduced adrenergic tone
Acute breathlessness at rest	Sudden alveolar flooding (acute pulmonary edema)
Pink frothy sputum	RBC transudation into alveoli due to high capillary pressure
Cough (worse at night)	Pulmonary interstitial edema stimulating cough receptors
Wheezing (“cardiac asthma”)	Peribronchial edema causing airway narrowing
Fatigue	Reduced cardiac output → skeletal muscle hypoperfusion
Reduced exercise tolerance	Impaired oxygen delivery to tissues
Palpitations	AF or sinus tachycardia secondary to SNS activation
Chest pain	Demand ischemia / ACS precipitating ADHF
Rapid weight gain	Fluid retention (RAAS activation)
Abdominal fullness	Hepatic congestion / ascites
Early satiety	Congested liver + gut edema
Nausea / vomiting	Splanchnic congestion
Confusion / altered sensorium	Cerebral hypoperfusion
Reduced urine output	Renal hypoperfusion + venous congestion
Nocturia (early HF)	Improved renal perfusion in supine position
Cold intolerance	Peripheral vasoconstriction
Anxiety / air hunger	Severe hypoxia in pulmonary edema

Signs of Left-Sided Congestion

Sign	Mechanism
Tachypnea	Hypoxia + J receptor stimulation
Use of accessory muscles	Increased work of breathing
Basal crackles (crepitations)	Alveolar/interstitial fluid
Widespread crackles	Severe pulmonary edema
Wheezing	Bronchial wall edema
Hypoxia (↓SpO₂)	V/Q mismatch
Cyanosis	Severe hypoxemia
S3 gallop	Rapid ventricular filling into dilated LV
S4 gallop (HFpEF)	Stiff ventricle with atrial contraction
Displaced apex beat	Dilated LV
Mitral regurgitation murmur	LV dilation → annular dilation

Signs of Right-Sided Congestion

Sign	Mechanism
Raised JVP	Elevated right atrial pressure
Hepatojugular reflux	Inability of RV to handle venous return
Peripheral pitting edema	Venous hypertension
Sacral edema (bedridden)	Dependent venous pooling
Ascites	Chronic hepatic congestion
Tender hepatomegaly	Passive venous congestion
Splenomegaly (chronic)	Long-standing portal congestion
Anasarca	Severe systemic congestion

Signs of Hypoperfusion (Low cardiac Output State)

Sign	Mechanism
Cool clammy extremities	SNS-mediated vasoconstriction
Delayed capillary refill	Poor peripheral perfusion
Hypotension	Reduced stroke volume
Narrow pulse pressure	Low forward flow
Tachycardia	Compensatory SNS activation
Weak peripheral pulses	Low cardiac output
Oliguria (<0.5 mL/kg/hr)	Renal hypoperfusion
Lactic acidosis	Tissue hypoxia
Altered mental status	Cerebral hypoperfusion

Atypical Presentation

Scenario	Why It Occurs
Elderly without dyspnea	Blunted symptom perception
Isolated confusion	Low CO state
GI symptoms dominant	Right HF predominance
Flash pulmonary edema	Sudden afterload increase (hypertensive crisis)
Normal EF with severe symptoms	HFpEF (diastolic dysfunction)

Laboratory Investigations

A. Natriuretic Peptides

Test	What It Reflects	What to Expect
BNP	Ventricular wall stretch	Elevated (>100 pg/mL in ER supports HF)
NT-proBNP	Prohormone fragment	>300 pg/mL (acute setting supports HF)

False high: CKD, elderly, sepsis
False low: Obesity

B. Cardiac Biomarkers (Troponin)

Why Order?	What to Expect
Rule out ACS	Mild elevation common
Risk stratification	Higher levels = worse prognosis

Troponin elevation ≠ always MI

C. Renal Function

Parameter	Expected Finding	Mechanism
Creatinine	Elevated	Renal hypoperfusion + venous congestion
BUN	Elevated	Reduced renal flow
BUN/Cr ratio	>20	Prerenal physiology

This may indicate cardiorenal syndrome.

D. Electrolytes

Electrolyte	Expected Finding	Why?
Sodium	Hyponatremia	RAAS + ADH activation
Potassium	Hyper/hypokalemia	Diuretics or renal dysfunction
Magnesium	Low	Diuretics

Hyponatremia = Poor prognostic marker.

E. Liver Function Tests

Finding	Mechanism
Elevated AST/ALT	Hypoperfusion (“shock liver”)
Elevated bilirubin	Congestive hepatopathy
Elevated ALP	Cholestasis from congestion

F. Lactate

Elevated in:

Cardiogenic shock
Severe hypoperfusion

Lactate > 2 mmol/L = tissue hypoxia

G. Complete Blood Count

Finding	Why?
Anemia	Precipitating factor
Leukocytosis	Infection trigger
Hemoconcentration	Aggressive diuresis

ECG (Mandatory in All)

Finding	Interpretation
Sinus tachycardia	Compensatory
Atrial fibrillation	Common precipitant
ST changes	ACS
LVH	Chronic hypertension
LBBB	Structural disease

Chest X-Ray

Finding	Mechanism
Cardiomegaly	Dilated LV
Kerley B lines	Interstitial edema
Bat-wing pattern	Alveolar edema
Pleural effusion	Elevated hydrostatic pressure
Upper lobe diversion	Pulmonary venous hypertension

Early ADHF may have normal CXR.

Echocardiography (Essential)

Should be done early in all new ADHF.

What to Assess:

1. LVEF

<40% → HFrEF
41–49% → HFmrEF
≥50% → HFpEF

2. Regional Wall Motion Abnormality→ Suggests ischemia

3. Diastolic Dysfunction—E/e′ > 15,LA enlargement

4. RV Function-TAPSE ↓ in RV failure

5. Valvular Disease

6. IVC Size-Plethoric, non-collapsible → high RA pressure

Lung Ultrasound

Finding	Meaning
B-lines	Interstitial edema
Pleural effusion	Congestion
Rapid reduction with therapy	Response to diuresis

More sensitive than CXR for early congestion.

Hemodynamic Monitoring-Pulmonary artery catheter

(Not routinely recommended )-indications are

Respiratory distress or impaired systemic perfusion with inadequate clinical assessment

Persistent HF symptoms and Unclear fluid status (wet or dry) and/or perfusion status (warm or cold)
Uncertain systemic or pulmonary vascular resistance
Worsening kidney function
To guide IV vasodilator or inotropic therapy
To guide potential mechanical cardiac support or heart transplant decisionsUsing Pulmonary Artery Catheter:

Hemodynamic Goals in ADHF

Parameter	Target (Goal)
Right Atrial Pressure (RAP)	< 8 mmHg
Pulmonary Capillary Wedge Pressure (PCWP)	< 15 mmHg
Systemic Vascular Resistance (SVR)	1000–1200 dynes-sec/cm⁵
Cardiac Index (CI)	≥ 2.2 L/min/m²
If CI remains low	—

Coronary Evaluation

Indicated if:

Suspected ACS,High-risk ECG changes,Elevated troponin

Additional Tests (Based on Clinical Suspicion)

Test	When to Order
Thyroid function	New AF
D-dimer	Suspected PE
Procalcitonin	Suspected infection
ABG	Severe respiratory distress

Diagnostic Criteria (ESC Approach)

According to ESC, ADHF diagnosis requires:

A. Symptoms ± Signs of HF

AND

B. Elevated natriuretic peptides

AND/OR

C. Objective evidence of structural/functional cardiac abnormality

BNP Cutoffs (ESC Emergency Setting)

Test	Rule-Out Value
BNP	< 100 pg/mL
NT-proBNP	< 300 pg/mL

If below these → HF unlikely.

Elevated values support diagnosis but are not specific.

Management

Most outpatient GDMT of heart failure should be continued during ADHF unless any specific contraindication

Drug	Continue?
ACEi/ARB/ARNI	Hold if hypotension/AKI
Beta-blocker	Continue unless shock
MRA	Usually continue
SGLT2 inhibitor	Can continue/start once stable

Oxygen Therapy

Target SpO₂ > 92%
Avoid routine oxygen if saturation normal

Non-Invasive Ventilation (CPAP/BiPAP)

Benefits:

↓ Preload
↓ Afterload
Improves oxygenation
Reduces intubation rate

Indicated in:

Acute pulmonary edema
Severe dyspnea

Intubation

Indications:Altered sensorium,Severe hypoxia,Cardiogenic shock

Use caution: Positive pressure can reduce preload in hypotensive patients.

Fluid administration Conditions

Inadequate end-organ perfusion — e.g., oliguria/AKI, rising lactate, altered mentation.
No significant pulmonary congestion — e.g., absence of diffuse B-lines.
No evidence of systemic venous congestion — e.g., no marked JVP elevation, hepatic/renal venous congestion, or significant peripheral edema.
Evidence of fluid responsiveness using dynamic assessment — e.g., PLR with LVOT-VTI increase, or another validated dynamic test.

After the fluid challenge:

Reassess BP/MAP, perfusion, urine output, lactate, RV/LV function and congestion.
If there is no meaningful improvement, stop giving fluid. Repeated blind fluid boluses can worsen RV dilation, septal shift and venous congestion.

Decongestion(fluid removal)

IV Loop Diuretics (First-Line)

Drug:-Furosemide/bumetanide IV(1 mg IV bumetanide = 40 mg IV furosemide)

Dosing Strategy: if chronic user: ≥ home oral dose IV equivalent.The DOSE-HF trial demonstrated that multiplying the oral diuretic dose by approximately 2.5 improves fluid and weight loss.

For loop diuretic naïve patients, this is often 40 to 80 mg of IV furosemide.

Urine Sodium–Guided Diuretic Strategy in Heart Failure

1. Rationale

Increasing evidence supports urine sodium–based monitoring for:

Assessing diuretic response
Early dose titration

More reliable than clinical markers alone (e.g., weight, edema)

2. Early Assessment of Diuretic Response

Timing

Urine sodium (UNa): 1–2 hours after IV loop diuretic
Urine output (UOP): within 2- 6 hours

Interpretation of Urine Sodium

< 50–70 mmol/L → Poor response
≥ 100 mmol/L → Good / excellent response
U/0 <150ml/hr-Poor response

3. Natriuretic Response Prediction

Uses spot urine sample
More accurate than urine sodium alone
Helps predict loop diuretic effectiveness early

4. Diuretic Titration Strategy

Initial Goal

Identify effective diuretic dose that produces adequate natriuresis

Then

Repeat/adjust dose to achieve target decongestion rate

5. Targets of Decongestion

Net sodium loss: 230–500 mmol/day
Net fluid loss: 3–5 L/day

(Always individualize based on patient status)

6: Escalation Strategy (if resistance persists)

Increase loop diuretic dose (stepwise doubling)
Add:

Thiazide (sequential nephron blockade)
SGLT2 inhibitor

Consider combination strategies early if poor natriuresis

7: Safety

Avoid excessive dosing
>1000 mg furosemide equivalent/day → caution
Monitor:

Electrolytes
Renal function

Diuretic Resistance

There is no fixed rule for when to add a thiazide to loop diuretics.

In practice, loop diuretic doses can be increased beyond usual “maximum” limits if needed.
In resistant cases, high doses may be used safely, such as:

IV bumetanide up to 12.5 mg
IV furosemide up to 500 mg

These higher doses are sometimes necessary when patients do not respond to standard treatment.

To improve (augment) diuretic response, mineralocorticoid receptor antagonists (MRAs) may be used in higher doses (>100 mg/day).

Giving hypertonic saline (3% NaCl) with diuretics can sometimes increase urine output, but this needs close monitoring (electrolytes, fluid status).

Ultrafiltration (UF) is another option in acute decompensated heart failure (ADHF):

It removes excess fluid directly from blood
Done using venovenous access (like dialysis)

Vasodilators (If BP > 110 mmHg)

1. who will benefit

HFrEF:

Vasodilators ↓ preload + afterload
→ ↑ cardiac output + rapid symptom relief
More beneficial

Mitral regurgitation
Very High MAP-Hypertensive urgency/emergency,High SVR on invasive monitoring

2. Types of Vasodilation

Nitroprusside→ Balanced, ↓preload + afterload, Preffered
NTG—best for SCAPE

3. Important Clinical Points

Nitrate tolerance develops within hours → need 8–12 hr nitrate-free interval
Hydralazine + nitrates:

Combined preload + afterload reduction
Use if ACEi/ARB not possible (e.g., renal failure, hyperkalemia, pregnancy)in the treatment of chronic HFrEF

Vasodilators in ADHF (Drug Table)

IV Vasodilators

Drug	Dose	Hemodynamic Effect
Enalaprilat	1.25 mg IV q6–8h 5 mg q6–8h(max dose)	Venous + arterial
Nitroprusside	0.2 mcg/kg/min 10 mcg/kg/min(max dose)	Balanced
Nitroglycerin	10 mcg/min 400 mcg/min(max dose)	Venous (low dose), arterial (high dose)

Oral Vasodilators(USED IN chronic HFrEF)

Drug	Initial Dose	Effect
Hydralazine	25 mg q6–8h 100 mg q6–8h(max dose)	Arterial
Isosorbide dinitrate	10 mg q6–8h 40 mg q6–8h(max dose)	Venous
Captopril	6.25 mg q8h 50 mg q8h(max dose)	Venous + arterial

Hypotension Management

Norepinephrine—First line
Epinephrine—for a patient with reduced ejection fraction, hypotension, and poor cardiac output.0-5 mcg/min acts as an inotrope.

Inotropes for HFrEF

Routine use in acute decompensated heart failure (ADHF) is not recommended.
Their harmful effects are due to increased intracellular calcium, which raises myocardial oxygen demand and significantly increases the risk of arrhythmias.
Indications—Hypoperfusion with low-normal blood pressure,Refractory cardiogenic pulmonary edema
Long-term use is limited to inotrope-dependent patients, mainly as a bridge to heart transplantation, mechanical circulatory support, or for palliative care.

Drug	Infusion Rate	Note
Dobutamine	2.5–5 μg/kg/min 20 μg/kg/min(max dose)	↑ CO, ↑ HR, ↓ SVR
Milrinone	0.25–0.375 μg/kg/min 0.75 μg/kg/min(max dose)	Preffered in right ventricular failure
Dopamine	2–5 μg/kg/min 20 μg/kg/min(max dose)	Dose-dependent

Digoxin—Preffered in long-standing atrial fibrillation and systolic heart failure

Fluid & Sodium Management

Sodium restriction (≤2 g/day)
Fluid restriction (1.5–2 L/day if hyponatremia)
Strict I/O monitoring
Daily weights

Guidelines recommend screening all heart failure patients for iron deficiency

Very common: seen in 50–80% of ADHF patients, even without anemia

Definition of Iron Deficiency (HFrEF)

Ferritin <100 ng/mL
OR
Ferritin 100–300 ng/mL + TSAT <20%

Oral iron NOT effective give iron.v iron only in divided dose

Mechanical circulatory support

Indicated when Everything above doesn’t work,Refractory to Pharmacological Treatment.

Options-Intra-aortic balloon pump,impella,VA-ECMO

Avoid this

Nephrotoxic medications (e.g. NSAIDs, ACEi/ARB)
Diltiazem for rate control in AF patients with decompensated heart failure
Trying to suppress Compensatory sinus tachycardia.
Treating mild Hyponatremia of heart failure origin.
Using B-Blockers in ADHF.

REFERENCES

1.Irwin and Rippe’s Intensive Care Medicine 9th edition